BC expands biosimilars program to include insulin

Dec 1, 2021

British Columbia announced that it has expanded its biosimilar program to include insulin.  About 30,000 patients will now have six months to transition to Admelog® (biosimilar insulin lispro) and Trurapi® (biosimilar insulin aspart).

Print Page Mail Article